Indivior Share Discussion Threads

[timmy11] 15/10/2020 11:01

standard life manipulating market

[grupo] 06/10/2020 11:24

A REDUCTION IN HOLDING

[grupo] 30/9/2020 14:25

who was affected and will they get recompense pally

[adrian j boris] 26/9/2020 07:22

The company also plans on developing its early-stage pipeline assets, including INDV-2000 for treating opioid use disorder and INDV-1000 for alcohol use disorder treatment.

[the grumpy old men] 24/9/2020 11:33

Indivior Reorganises Amid Challenges; Still In Line With Expectations

Thu, 24th Sep 2020 10:44

(Alliance News) - Indivior PLC on Thursday said it is taking organisational and cost actions amid the challenges posed by the Covid-19 pandemic.

Indivior is a US-based pharmaceutical company focused on the treatment of opioid addiction and mental illnesses.

Indivior expects to reduce its operating expense base by between USD60.0 million to USD70.0 million pre-tax in 2021 compared with its expected operating expense base in 2020, the company said.

A restructuring charge of approximately USD6.0 million to pay for this will be booked as an exceptional item in the third quarter of 2020.

Indivior says the restructuring involves reorganizing and reinvesting in the US commercial function, focusing on research & development on post-marketing studies to support its Subcolade and Perseris products, the former used to treat opioid addiction and the latter used to treat schizophrenia. Finally, the company will focus on the development of early-stage pipeline assets.

Indivior says business performance during the third quarter has been in-line with the financial year's planning assumptions, with the exception that its Suboxone Film, a prescription medicine used to treat opioid addiction. This has continued to perform ahead of expectations.

Indivior shares were up 5.9% at 122.60 pence each on Thursday morning in London.

By Greg Roxburgh; [e-mail]

[the grumpy old men] 24/9/2020 09:54

Oliver Haill

09:00 Thu 24 Sep 2020


Indivior cutting jobs as part of product refocus

Within the pipeline, the priorities include a potential treatment of alcohol use disorder

Suboxone sales are not declining as expected

Indivior PLC (LON:INDV) said it is cutting jobs and reducing discretionary spending to save money as its further shifts its emphasis away from its Suboxone Film anti-opioid-addiction product.

The reorganisation will see a shift towards the US sales functions to focus on the 'organised health system' for its Sublocade monthly anti-opioid-addiction injection and its Perseris treatment for the treatment of schizophrenia.
READ: Indivior soars as it reaches settlement with US authorities over Suboxone lawsuit

This includes hiring and redirecting some employees from other parts of the business.

Group performance during the third quarter has been in-line with the 'planning assumptions' given at its interim results in July, apart from Suboxone performing better than expected.

The company, which was spun out of Reckitt Benckiser in 2014, said it was also going to focus more research & development on “post-marketing studies” to support these two products, as well as on its early-stage pipeline assets.

Within the pipeline, the priorities are INDV-2000, another potential treatment for opioid use disorder, and INDV-1000, a potential treatment of alcohol use disorder.

As well as streamlining certain corporate functions, reduced discretionary spending will include suspending bonus increases and lowering third-party expenditure.

Indivior, which has operations in Slough, England and Richmond, Virginia, USA, expects to cut its cost base by US$60-70mln in 2021.

Chief executive Mark Crossley said: “We are taking the right strategic actions on organizational focus and cost management to better align our capabilities and resources with the group's near- and medium-term priorities, while also supporting our long-term growth ambitions.”

Proactiveinvestors

[the grumpy old men] 24/9/2020 09:40

Michele Maatouk
Sharecast News
24 Sep, 2020 09:23 24 Sep, 2020 09:25
Indivior to axe jobs, restructure as it looks to cut costs


Opioid addiction treatment maker Indivior outlined plans on Thursday to reduce costs through job cuts and restructuring, as it looks to support long-term growth ambitions and protect its financial and operational flexibility in response to the pandemic.

The company said it will reorganise and reinvest in the US commercial function in-line with the continued penetration and growth of Sublocade. It will also focus research and development on post-marketing studies to support Sublocade and Perseris.

Indivior said it will be "streamlining" certain corporate functions and reducing discretionary spending, including suspending merit-based pay rises and lowering third-party expenditures.

Based on these measures, it expects to cut its operating expense base by between $60m and $70m pre-tax in 2021.

The company said its third-quarter performance has been in-line with the expectations outlined at the end of July, with the exception that Suboxone Film share has continued to perform ahead of historical industry analogues and group expectations.

Chief executive officer Mark Crossley said: "We are taking the right strategic actions on organisational focus and cost management to better align our capabilities and resources with the group’s near- and medium-term priorities, while also supporting our long-term growth ambitions.

"While some of the expected savings will be reinvested to support the continued growth of Sublocade and Perseris in the US and targeted international geographies, we will retain a large portion of the expected savings to preserve the group’s flexibility through the Covid-19 pandemic. In addition, we are maintaining our core capabilities in addiction science to support drug discovery and development."

As far as jobs are concerned, Crossley said that while some teams will remain unchanged, others will be reduced "to align with our strategic priorities".

[the grumpy old men] 24/9/2020 08:52

RNS Number : 9398Z

Indivior PLC

24 September 2020

Indivior Takes Strategic Alignment Actions

This release contains inside information.

Slough, United Kingdom and Richmond, Virginia - September 24, 2020 - Indivior PLC (LON: INDV) today announced that it is taking organizational and cost actions to better align its capabilities and resources with the Group's strategic priorities. These actions further consider Indivior's strategy and are intended to enhance the Group's commercial and R&D focus on the highest value opportunities, protect the Group's financial and operational flexibility in response to ongoing challenges posed by the COVID-19 pandemic and support the Group's long-term growth ambitions.

Key actions Indivior is taking include:

-- Reorganizing and reinvesting in the U.S. commercial function in-line with the continued penetration and growth of SUBLOCADE (R) (buprenorphine extended-release) Injection in the Organized Health System (OHS) channel and to facilitate expansion of PERSERIS (R) (risperidone) extended release injection into the OHS channel. This includes hiring and redirecting some employees to further our progress in this channel.

-- Further focusing of R&D on post-marketing studies to support SUBLOCADE(R) and PERSERIS(R) and on the development of early-stage pipeline assets with the prioritization of INDV-2000 (selective Orexin-1 receptor antagonist) for the treatment of opioid use disorder and INDV-1000 (selective GABAb positive allosteric modulator) for the treatment of alcohol use disorder .

-- Streamlining certain corporate functions and reducing discretionary spending, including suspending merit-based pay increases and lowering third-party expenditures.

Comment by Mark Crossley, CEO of Indivior PLC:

"We are taking the right strategic actions on organizational focus and cost management to better align our capabilities and resources with the Group's near- and medium-term priorities, while also supporting our long-term growth ambitions. While some of the expected savings will be reinvested to support the continued growth of SUBLOCADE(R) and PERSERIS(R) in the U.S. and targeted international geographies, we will retain a large portion of the expected savings to preserve the Group's flexibility through the COVID-19 pandemic. In addition, we are maintaining our core capabilities in addiction science to support drug discovery and development. These actions will result in a stronger organization with an improved cost position and the ability to continue to make investments to strengthen the global delivery platforms for SUBLOCADE(R) and PERSERIS(R). Critically, we are maintaining our strong commitment to integrity and compliance."

"These actions, unfortunately, will impact our workforce as we are reorganizing and reallocating healthcare practitioner-facing resources in the U.S. toward Organized Health Systems, streamlining certain corporate functions and reducing discretionary expenses. While some teams will remain unchanged, others will be reduced in size to align with our strategic priorities. As always, we will look to support those that will be departing the Group."

Based on the actions set out above, Indivior expects to reduce its operating expense base (SG&A plus R&D) by between $60m to $70m pre-tax in 2021 compared with its expected operating expense base in 2020 on an adjusted basis, excluding exceptional items. For reference, Indivior's H1 2020 adjusted operating expenses were $242m and the Group's FY 2020 Planning Assumptions include a slightly lower level of operating expenses on an adjusted basis in H2 2020 compared with H1 2020. A restructuring charge of approximately $6m will be booked as an exceptional item in the Q3 2020 financial results (which are scheduled to be reported on October 29, 2020). Actions associated with the key elements of the program are expected to be completed in the fourth quarter of 2020.

Indivior notes that business performance during the third quarter of 2020 has been in-line with the FY 2020 Planning Assumptions it outlined on July 30(th) as part of its H1 2020 results announcement, with the exception that SUBOXONE(R) Film share has continued to perform ahead of historical industry analogues (1) and Group expectations.

(1) IMS Institute Report, January 2016, "Price Declines after Branded Medicines Lose Exclusivity in the U.S."

[steeplejack] 24/9/2020 08:49

Indivior notes that business performance during the third quarter of 2020 has been in-line with the FY 2020 Planning Assumptions it outlined on July 30th as part of its H1 2020 results announcement, with the exception that SUBOXONE® Film share has continued to perform ahead of historical industry analogues (1) and Group expectations.

[maywillow] 21/9/2020 19:41

NOW THATS A REAL JUMP BUT WHY


INDIVIOR PLC (INVVY)

Delayed Quote. Delayed OTC Bulletin Board - Other OTC - 09/21 07:26:46 pm

10.88 USD +37.20%

[waldron] 21/9/2020 09:21

Upcoming events on INDIVIOR

October/29/2020 Q3 2020 Earnings Release

[grupo] 21/9/2020 08:50

Price (GBX)
115.90 -4.69% (-5.70)

Open / Last close
122.70 / 121.60

High / Low
124.60 / 115.80

Bid / Offer
115.90 / 116.30

Special Condition: -
Trading Status: Regular Trading
FTSE All-Share
As at 21.09.20 08:33:05 - All data delayed at least 15 minutes

[jgrabar] 09/9/2020 12:37

Longer term INDV holders can make demands for governance reforms and seek restitution on behalf of the company, for the failures in corporate governance the lead to the guilty pleas and $600 million fines. Cash incentives are typically awarded to the demanding shareholder(s) as well. Another side of investing when these situations arise. Feel free to message me here to learn more.

[meijiman] 09/9/2020 12:31

It's the electric chair for him then.......

[grupo] 05/9/2020 18:15

RNS Number : 1399Y

Indivior PLC

04 September 2020

September 4, 2020

Indivior PLC - Board Announcement

Indivior PLC announces that the Chair of the Board, Howard Pien, who has been on a medical leave since June 15, 2020, has notified the Board of his resignation with immediate effect.

Daniel Tassé, who was appointed as Interim Chair in Mr Pien's absence, will continue to act as Interim Chair until the Board appoints Mr Pien's successor. The Board will commence a process to identify a successor.

Mr Tasse joined the Board in 2014 and was appointed Senior Independent Director in 2016 ( bio ). He is a member of the Audit and Remuneration Committees.

[ariane] 04/9/2020 18:37

Fri, 4th Sep 2020 17:31
RNS Number : 1399Y
Indivior PLC
04 September 2020


September 4, 2020



Indivior PLC - Board Announcement



Indivior PLC announces that the Chair of the Board, Howard Pien, who has been on a medical leave since June 15, 2020, has notified the Board of his resignation with immediate effect.



Daniel Tassé, who was appointed as Interim Chair in Mr Pien's absence, will continue to act as Interim Chair until the Board appoints Mr Pien's successor. The Board will commence a process to identify a successor.



Mr Tasse joined the Board in 2014 and was appointed Senior Independent Director in 2016 (bio). He is a member of the Audit and Remuneration Committees.



Investor Contact:

Jason Thompson, IndiviorVice President, Investor Relations+1 [e-mail]

[adrian j boris] 02/9/2020 20:38

FTSE 250 Adds:



Indivior

[sarkasm] 01/9/2020 10:21

Newtyn Management, LLC




New York, United States

Just bought near 4pc

[waldron] 31/8/2020 08:38

THE WISH LIST GIVING BOXES,Supports and Resistences to determine channels and trends together with broker targets which might of course make you smile or and smirk


90 to 100p
110 to 120p$$$$$$$$$$$$$ WE ARE HERE $$$$$$$$$$$$$$$
120 to 130p
130 to 140p
140 to 150p
150 to 160p
160 to 170pCiti target 165p
170 to 180p
180 to 190p
190 to 200p Jefferies target 200p





DECEMBER END 2019 GIVES 39p which puts us into the 30 to 40p BOX again


June ends in the 80 to 90p BOX at 83p

July ends at 137.60p

August ends at 118.70p


current strong support seems to be 111p

current strong resistence seems to be 142.40p

[waldron] 28/8/2020 07:48

It seems theres possible strong support at 111p